Tubulins as therapeutic targets in cancer: From bench to bedside

Current Pharmaceutical Design

Volumn 18, Issue 19, 2012, Pages 2778-2792

  Katsetos, Christos D ^a   Dráber, Pavel ^b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b INSTITUTE OF MATHEMATICS   (Czech Republic)

Author keywords

Beta tubulin isotypes; Cancer; Epothilones; Gamma tubulin; Gliomas; Microtubules; Solid tumors; Spastin; Tubulin; Tubulin binding agent(s)

Indexed keywords

2 METHOXYESTRADIOL; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BETA TUBULIN; CISPLATIN; COLCHICINE; DIMER; DOCETAXEL; EPOTHILONE B; GAMMA TUBULIN; GUANOSINE TRIPHOSPHATASE; IXABEPILONE; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; SAGOPILONE; SPASTIN; SULFONAMIDE; TAXANE DERIVATIVE; TEMOZOLOMIDE; TUBULIN; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER THERAPY; CELL MOTILITY; CELL PROLIFERATION; CLINICAL TRIAL; COMPUTER MODEL; DRUG BINDING SITE; DRUG TARGETING; GLIOBLASTOMA; GLIOMA; HUMAN; LUNG NON SMALL CELL CANCER; MICROTUBULE; NEUTROPENIA; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY CANCER; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW;

EID: 84862580438     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212800626193     Document Type: Review

References (212)

1. Kreis T, Vale R. Guidebook to the cytoskeletal and motor proteins. Oxford: Oxford University Press 1993.
2. Katsetos CD, Herman MM, Mörk SJ. Class III tubulin in human development and cancer. Cell Motil Cytoskeleton 2003; 55: 77-96.
3. Katsetos CD, Legido A, Perentes E, Mörk SJ. Class III-tubulin isotype: a key cytoskeletal protein at the crossroads of developmental neurobiology and tumor, neuropathology. J Child Neurol 2003; 18: 851-66.
4. Katsetos CD, Dráberová E, Legido A, Dumontet C, Dráber P. Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. Class III b-tubulin. J Cell Physiol 2009; 221: 505-13.
5. Katsetos CD, Dráberová E, Legido A, Dráber P. Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. II.-Tubulin. J Cell Physiol 2009; 221: 514-20.
6. Katsetos CD, Dráber P, Kavallaris M. Targeting III-tubulin in glioblastoma multiforme: from cell biology and histopathology to cancer therapeutics. Anticancer Agents Med Chem 2011; 11: 719-28.
7. Jordan MA, Wilson L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 1998; 10: 123-30.
8. Pasquier E, Kavallaris M. Microtubules: a dynamic target in cancer therapy. IUBMB Life 2008; 60: 165-70.
9. Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 2010; 9: 790-803.
10. Whipple RA, Cheung AM, Martin SS. Detyrosinated microtubule protrusions in suspended mammary epithelial cells promote reattachment. Exp Cell Res 2007; 313: 1326-36.
11. Schoumacher M, Goldman RD, Louvard D, Vignjevic DM. Actin, microtubules, and vimentin intermediate filaments cooperate for elongation of invadopodia. J Cell Biol. 2010; 189: 541-56.
12. Liaw TY, Chang MH, Kavallaris, M. The cytoskeleton as a therapeutic target in childhood acute leukemia: obstacles and opportunities. Curr Drug Targets 2007; 8: 739-49.
13. Ferlini C, Raspaglio G, Cicchillitti L, et al. Looking at drug resistance mechanisms for microtubule interacting drugs: does TUBB3 work? Curr Cancer Drug Targets 2007; 7: 704-12.
14. Kavallaris, M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 2010; 10: 194-204.
15. Nogales E, Wolf SG, Downing KH. Structure of the ab tubulin dimer by electron crystallography. Nature 1998; 391: 199-203.
16. Löwe J, Li H, Downing KH, Nogales E. Refined structure of abtubulin at 3.5 A resolution. J Mol Biol 2001; 313: 1045-57.
17. Li H, DeRosier DJ, Nicholson WV, Nogales E, Downing KH. Microtubule structure at 8 A resolution. Structure 2002; 10: 1317-28.
18. Nogales E, Whittaker M, Milligan RA, Downing KH. Highresolution model of the microtubule. Cell 1999; 96: 79-88.
19. Wade RH, Hyman AA. Microtubule structure and dynamics. Curr Opin Cell Biol 1997; 9: 12-17.
20. Downing KH. Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics. Annu Rev Cell Dev Biol 2000; 16: 89-111.
21. Amos LA, Schlieper D. Microtubules and maps. Adv Protein Chem 2005; 71: 257-98.
22. Akhmanova A, Steinmetz MO. Tracking the ends: a dynamic protein network controls the fate of microtubule tips. Nat Rev Mol Cell Biol 2008; 9: 309-22.
23. Ludueña RF. The multiple forms of tubulin: different gene products and covalent modifications. Int Rev Cytol 1998; 178: 207-75.
24. Ludueña RF, Banerjee A. The isotypes of tubulin: distribution and functional, significance. In: Fojo T, Ed., Cancer drug discovery and development: the role of microtubules in cell biology, neurobiology, and oncology. Totowa, NJ: Humana Press 2008, pp. 123-175.
25. Verdier-Pinard P, Pasquier E, Xiao H, et al. Tubulin proteomics: towards breaking the code. Anal Biochem 2009; 384: 197-206.
26. Downing KH, Nogales E. Tubulin and microtubule structure. Curr Opin Cell Biol 1998; 10: 16-22.
27. Bhattacharya R, Cabral F. A ubiquitous b-tubulin disrupts microtubule assembly and inhibits cell proliferation. Mol Biol Cell 2004; 15: 3123-31.
28. Sullivan KF. Structure and utilization of tubulin isotypes. Ann Rev Cell Biol 1988; 4: 687-716
29. Guo J, Walss-Bass C, Ludueña RF. The isotypes of tubulin in neuronal differentiation. Cytoskeleton 2010; 67: 431-41.
30. Guo J, Qiang M, Ludueña RF. The distribution of tubulin isotypes in cultured neurons from embryonic, newborn, and adult mouse brains. Brain Res 2011; 1420: 8-18
31. Jordan MA, Kamath K. How do microtubule-targeted drugs work? An overview. Curr Cancer Drug Targets 2007; 7: 730-42.
32. Ludueña RF, Banerjee A. The post-translational modifications of tubulin. In: Fojo T, Ed. Cancer Drug Discovery and Development: The Role of Microtubules in Cell Biology, Neurobiology, and Oncology. Totowa, NJ: Humana Press 2008; pp. 105-121.
33. Joe PA, Banerjee A, Ludueña RF. The roles of cys124 and ser239 in the functional properties of human betaIII tubulin. Cell Motil Cytoskeleton 2008; 65: 476-86.
34. Khan IA, Ludueña RF. Phosphorylation of III-tubulin. Biochemistry 1996; 35: 3704-11.
35. Joe PA, Banerjee A, Ludueña RF. Roles of tubulin residues Ala428 and Thr429 in microtubule formation in vivo. J Biol Chem 2009; 284: 4283-91.
36. Dráberová E, Luká Z, Ivanyi D, Viklick V, Dráber P. Expression of class III tubulin in normal and neoplastic human tissues. Histochem Cell Biol 1998; 109: 231-39.
37. Katsetos CD, Herman MM, Frankfurter A, Uffer S, Perentes E, Rubinstein LJ. Neuron-associated class III tubulin isotype, microtubule-associated protein 2, and synaptophysin in human retinoblastomas in situ. Further immunohistochemical observations on the Flexner-Wintersteiner rosettes. Lab Invest 1991; 64: 45-54.
38. Katsetos CD, Frankfurter A, Christakos S, Mancall EL, Vlachos I, Urich H. Differential localization of class III tubulin isotype and calbindin-D28k defines distinct neuronal types in the developing human cerebellar cortex. J Neuropathol Exp Neurol 1993; 52: 655-66.
39. Katsetos CD, Karkavelas G, Herman MM, et al. Class III tubulin isotype (III) in the adrenal medulla: I. Localization in the developing human adrenal medulla. Anat Rec 1998; 250: 335-43.
40. Kukharskyy V, Sulimenko V, Macrek L, Sulimenko T, Dráberová E, Dráber P. Complexes of-tubulin with non-receptor protein tyrosine kinases Src and Fyn in differentiating P19 embryonal carcinoma cells. Exp Cell Res 2004; 298: 218-28.
41. Dráberová E, Del Valle L, Gordon J, et al. Class III-tubulin is constitutively coexpressed with glial fibrillary acidic protein and nestin in midgestational human fetal astrocytes: implications for phenotypic identity. J Neuropathol Exp Neurol 2008; 67: 341-54.
42. Little M, Ludueña RF. Structural differences between brain beta 1-and beta 2-tubulins: implications for microtubule assembly and colchicine binding. EMBO J 1985; 4: 51-6.
43. Bai RL, Lin CM, Nguyen NY, Liu TY, Hamel E. Identification of the cysteine residue of beta-tubulin alkylated by the antimitotic agent 2,4-dichlorobenzyl thiocyanate, facilitated by separation of the protein subunits of tubulin by hydrophobic column chromatography. Biochemistry. 1989; 28: 5606-12.
44. Bhattacharya R, Cabral F. Molecular basis for class V beta-tubulin effects on microtubule assembly and paclitaxel resistance. J Biol Chem 2009; 284: 13023-32.
45. Wang D, Villasante A, Lewis SA, Cowan NJ. The mammalian b-tubulin repertoire: hematopoietic expression of a novel, heterologous beta-tubulin isotype. J Cell Biol 1986; 103: 1903-10.
46. Murphy DB, Wallis KT, Machlin PS, Ratrie H III, Cleveland DW. The sequence and expression of the divergent beta-tubulin in chicken erythrocytes. J Biol Chem 1987; 262: 14305-12.
47. Schwer, HD, Lecine P, Tiwari S, Italiano JE Jr, Hartwig JH, Shivdasani RA. A lineage-restricted and divergent beta-tubulin isoform is essential for the biogenesis, structure and function of blood platelets. Curr Biol 2001; 11: 579-86.
48. Linhartová I, Dráber P, Dráberová, E, Viklick V. Immunological discrimination of tubulin isoforms in developing mouse brain. Post-translational modification of non-class III-tubulins. Biochem J 1992; 288: 919-24.
49. Wolff A, Denoulet P, Jeantet C. High level of tubulin microheterogeneity in the mouse brain. Neurosci Lett 1982; 31: 323-28.
50. Wloga D, Gaertig J. Post-translational modifications of microtubules. J Cell Sci 2010; 123: 3447-55.
51. Verhey KJ, Gaertig J. The tubulin code. Cell Cycle 2007; 6: 2152-60.
52. Westermann S, Weber K. Post-translational modifications regulate microtubule function. Nat Rev Mol Cell Biol 2003; 4: 938-47.
53. Palazzo AF, Eng CH, Schlaepfer DD, Marcantonio EE, Gundersen GG. Localized stabilization of microtubules by integrinand FAK-facilitated Rho signaling. Science 2004; 303: 836-9.
54. Janke C, Kneussel M. Tubulin post-translational modifications: encoding functions on the neuronal microtubule cytoskeleton. Trends Neurosci 2010; 33: 362-72.
55. Janke C, Rogowski K, van DJ. Polyglutamylation: a fine-regulator of protein function? EMBO Rep 2008; 9: 636-41.
56. Lacroix B, van DJ, Gold ND, et al. Tubulin polyglutamylation stimulates spastin-mediated microtubule severing. J Cell Biol 2010; 189: 945-54.
57. Cai D, McEwen DP, Martens JR, Meyhofer E, Verhey KJ. Single molecule imaging reveals differences in microtubule track selection between kinesin motors. PLoS Biol 2009; 7: e1000216.
58. Oakley CE, Oakley BR. Identification of-tubulin, a new member of the tubulin superfamily encoded by mipA gene of Aspergillus nidulans. Nature 1989; 338: 662-4.
59. Stearns T, Evans L, Kirschner M.-Tubulin is highly conserved component of the centrosome. Cell 1991; 65: 825-36.
60. Lajoie-Mazenc I, Tollon I, Détraves C, et al. Recruitment of antigenic gamma-tubulin during mitosis in animal cells: presence of gamma-tubulin in the mitotic spindle. J Cell Sci 1994; 107: 2825-37.
61. Nováková M, Dráberová E, Schürmann W, Czihak G, Viklick V, Dráber P. Tubulin redistribution in taxol-treated mitotic cells probed by monoclonal antibodies. Cell Motil Cytoskeleton 1996; 33: 38-51.
62. Julian M, Tollon Y, Lajoie-Mazenc I, et al. Tubulin participates in the formation of midbody during cytokinesis in mammalian cells. J Cell Sci 1993; 105: 145-56.
63. Murphy SM, Urbani L, Stearns T. The mammalian-tubulin complex contains homologues of the yeast spindle pole body components Spc97p and Spc98p. J Cell Biol 1998; 141: 663-74.
64. Kollman JM, Zelter A, Muller EG, et al. The structure of the tubulin small complex: implications of its architecture and flexibility for microtubule nucleation. Mol Biol Cell 2008; 19: 207-15.
65. Kollman JM, Polka JK, Zelter A, Davis TN, Agard DA. Microtubule nucleating-TuSC assembles structures with 13-fold microtubule-like symmetry. Nature 2010; 466: 879-882.
66. Murphy SM, Preble AM, Patel UK, et al. GCP5 and GCP6: two new members of the human-tubulin complex. Mol Biol Cell 2001; 12: 3340-52.
67. Lüders J, Patel UK, Stearns T. GCP-WD is a-tubulin targeting factor required for centrosomal and chromatin-mediated microtubule nucleation. Nat Cell Biol 2006; 8: 137-47.
68. Moritz M, Braunfeld MB, Guenebaut V, Heuser J, Agard DA. Structure of the-tubulin ring complex: a template for microtubule nucleation. Nat Cell Biol 2000; 2: 365-70.
69. Schnackenberg BJ, Palazzo RE. Reconstitution of centrosome microtubule nucleation in Spisula. Methods Cell Biol 2001; 67: 149-65.
70. Wiese C, Zheng Y. A new function for the-tubulin ring complex as a microtubule minus-end cap. Nat Cell Biol 2000; 2: 358-64.
71. Leguy R, Melki R, Pantaloni D, Carlier MF. Monomeric-tubulin nucleates microtubules. J Biol Chem 2000; 275: 21975-80.
72. Linhartová I, Novotná B, Sulimenko V, Dráberová E, Dráber P. Gamma-tubulin in chicken erythrocytes: changes in localization during cell differentiation and characterization of cytoplasmic complexes. Dev Dyn 2002; 223: 229-40.
73. Bugnard E, Zaal KJM, Ralston E. Reorganization of microtubule nucleation during muscle differentiation. Cell Motil Cytoskeleton 2005; 60: 1-13.
74. Chabin-Brion K, Marceiller J, Perez F, et al. The Golgi complex is a microtubule-organizing organelle. Mol Biol Cell 2001; 12: 2047-60.
75. Dryková D, Sulimenko V, Cenklová V, Volc J, Dráber P, Binarová P. Plant-tubulin interacts with-tubulin dimers and forms membrane-associated complexes. Plant Cell 2003; 15: 465-80.
76. Efimov A, Kharitonov A, Efimova N, et al. Asymmetric CLASP-dependent nucleation of noncentrosomal microtubules at the transGolgi network. Dev Cell 2007; 12: 917-30.
77. Macurek L, Dráberová E, Richterová V, et al. Regulation of microtubule nucleation in differentiating embryonal carcinoma cells by complexes of membrane-bound-tubulin with Fyn kinase and phosphoinositide 3-kinase. Biochem J 2008; 416: 421-30.
78. Bouissou A, Verollet C, Sousa A, et al. Tubulin ring complexes regulate microtubule plus end dynamics. J Cell Biol 2009; 187: 327-34.
79. Raynaud-Messina B, Merdes A. Tubulin complexes and microtubule organization. Curr Opin Cell Biol 2007; 19: 24-30.
80. Hor̃ejí B, Vinopal S, Sládková V, et al. Nuclear gamma-tubulin associates with nucleoli and interacts with tumor suppressor protein C53. J Cell Physiol 2012; 227: 367-82.
81. Höög G, Zarrizi R, von Stedingk K, Jonsson K, Alvarado-Kristensson M. Nuclear localization of-tubulin affects E2F transcriptional activity and S-phase progression. The FASEB J 2011; 25: 3815-27.
82. Wise DO, Krahe R, Oakley BR. The-tubulin gene family in humans. Genomics 2000; 67: 164-70.
83. Moudjou M, Bordes N, Paintrand M, Bornens M. Tubulin in mammalian cells: the centrosomal and the cytosolic forms. J Cell Sci 1996; 109: 875-87.
84. Sulimenko V, Sulimenko T, Poznanovic S, et al. Association of brain-tubulins with-tubulin dimers. Biochem J 2002; 365: 889-95.
85. Stumpff J, Kellogg DR, Krohne KA, Su TT. Drosophila Wee1 interacts with members of the TURC and is required for proper mitotic-spindle morphogenesis and positioning. Curr Biol 2005; 15: 1525-34.
86. Vogel J, Drapkin B, Oomen J, Beach D, Bloom K, Snyder M. Phosphorylation of-tubulin regulates microtubule organization in budding yeast. Dev Cell 2001; 1: 621-31.
87. Starita LM, Machida Y, Sankaran S, et al. BRCA1-dependent ubiquitination of-tubulin regulates centrosome number. Mol Cell Biol 2004; 24: 8457-66.
88. lyn form complexes with-tubulin in rat basophilic leukemia cells. Int Immunol 1999; 11: 1829-39.
89. Sulimenko V, Dráberová E, Sulimenko T, et al. Regulation of microtubule formation in activated mast cells by complexes of tubulin with Fyn and Syk kinases. J Immunol 2006; 176: 7243-53.
90. Feng Y, Hodge DR, Palmieri G, Chase DL, Longo DL, Ferris DK. Association of polo-like kinase with-, and-tubulins in a stable complex. Biochem J 1999; 339: 435-42.
91. Trinczek B, Brajenovic M, Ebneth A, Drewes G. MARK4 is a novel microtubule-associated proteins/microtubule affinityregulating kinase that binds to the cellular microtubule network and to centrosomes. J Biol Chem 2004; 279: 5915-23.
92. Colello D, Reverte CG, Ward R, et al. Androgen and Src signaling regulate centrosome activity. J Cell Sci 2010; 123: 2094-102.
93. Kapeller R, Toker A, Cantley LC, Carpenter CL. Phosphoinositide 3-kinase binds constitutively to α/β-tubulin and binds to-tubulin in response to insulin. J Biol Chem 1995; 270: 25985-91.
94. Lyle K, Kumar P, Wittmann T. SnapShot: Microtubule Regulators I. Cell 2009; 136: 380.
95. Lyle K, Kumar P, Wittmann T. SnapShot: Microtubule regulators II. Cell 2009; 136: 566.
96. Wade RH. On and around microtubules: an overview. Mol Biotechnol 2009; 43: 177-91.
97. Zhang D, Rogers GC, Buster DW, Sharp DJ. Three microtubule severing enzymes contribute to the Pacman-flux machinery that moves chromosomes. J Cell Biol 2007; 177: 231-42.
98. Roll-Mecak A, McNally FJ. Microtubule-severing enzymes. Curr Opin Cell Biol 2010; 22: 96-103.
99. Heald R, Nogales E. Microtubule dynamics. J Cell Sci 2002; 115: 3-4.
100. Sève P, Dumontet C. Is class III-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol 2008; 9: 168-75.
101. Dumontet C, Jordan MA, Lee FF. Ixabepilone: targeting III-tubulin expression in taxane-resistant malignancies. Mol Cancer Ther 2009; 8: 17-25.
102. Katsetos CD, Del Valle L, Legido A, de Chadarevian JP, Perentes E, Mörk SJ. On the neuronal/neuroblastic nature of medulloblastomas: a tribute to Pio del Rio Hortega and Moises Polak. Acta Neuropathol (Berl) 2003; 105: 1-13.
103. Katsetos CD, Kontogeorgos G, Geddes JF, et al. Differential distribution of the neuron-associated class III-tubulin in neuroendocrine lung tumors. Arch Pathol Lab Med 2000; 124: 535-44.
104. Dumontet C, Isaac S, Souquet PJ, et al. Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer 2005; 92: E25-30.
105. Sève P, Mackey J, Isaac S, et al. Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with nonsmall cell lung cancer receiving paclitaxel. Mol Cancer Ther 2005; 4: 2001-7.
106. Sève P, Isaac S, Trédan O, et al. Expression of class III-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 2005; 11: 5481-6.
107. Sève P, Lai R, Ding K, et al. Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res 2007; 13: 994-9.
108. Mozzetti S, Ferlini C, Concolino P, et al. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 2005; 11: 298-305.
109. Ferrandina G, Zannoni GF, Martinelli E, et al. Class III betatubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res 2006; 12: 2774-9.
110. Ferrandina G, Martinelli E, Zannoni GF, et al. Expression of class III beta tubulin in cervical cancer patients administered preoperative radiochemotherapy: correlation with response to treatment and clinical outcome. Gynecol Oncol 2007; 104: 326-30.
111. Ohishi Y, Oda Y, Basaki Y, et al. Expression of beta-tubulin isotypes in human primary ovarian carcinoma. Gynecol Oncol 2007; 105: 586-92.
112. Bernard-Marty C, Treilleux I, Dumontet C, et al. Microtubuleassociated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study. Clin Breast Cancer. 2002; 3: 341-5.
113. Hasegawa S, Miyoshi Y, Egawa C, et al. Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNA expression in human breast cancers. Clin Cancer Res 2003; 9: 2992-7.
114. Paradiso A, Mangia A, Chiriatti A, et al. Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann Oncol. 2005; 16 Suppl 4: 414-19.
115. Shalli K, Brown I, Heys SD, Schofield AC. Alterations of-tubulin isotypes in breast cancer cells resistant to docetaxel. FASEB J 2005; 19: 1299-301.
116. Tommasi S, Mangia A, Lacalamita R, et al. Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins. Int J Cancer 2007; 120: 2078-85.
117. Galmarini CM, Treilleux I, Cardoso F, et al. Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel. Clin Cancer Res 2008; 14: 4511-6.
118. Urano N, Fujiwara Y, Doki Y, et al. Clinical significance of class III beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer. Int J Oncol 2006; 28: 375-81.
119. Carles G, Braguer D, Dumontet C, et al. Differentiation of human colon cancer cells changes the expression of beta tubulin isotype and MAPs. Br J Cancer 1999; 80: 1162-8.
120. Portyanko A, Kovalev P, Gorgun J, Cherstvoy E. III-tubulin at the invasive margin of colorectal cancer: possible link to invasion. Virchows Archiv 2009: 454: 541-8.
121. Jirásek T, Mandys V, Viklick V. Expression of class III-beta tubulin in neuroendocrine tumors of gastrointestinal tract. Histochem Cytobiol 2002; 40: 305-10.
122. Lee KM, Cao D, Itami A, et al. Class III-tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia. Histopathology 2007; 51: 539-46.
123. Ranganathan S, Salazar H, Benetatos CA, Hudes GR. Immunohistochemical analysis of beta-tubulin isotypes in human prostate carcinoma and benign prostatic hypertrophy. Prostate. 1997; 30: 263-8.
124. Terry S, Ploussard G, Allory Y, et al. Increased expression of class III-tubulin in castration-resistant human prostate cancer. Br J Cancer 2009; 101: 951-6.
125. Egevad L, Valdman A, Wiklund NP, Sève P, Dumontet C. Betatubulin III expression in prostate cancer. Scand J Urol Nephrol 2010; 44: 371-7.
126. Katsetos CD, Del Valle L, Geddes JF, et al. Aberrant localization of the neuronal class III-tubulin in astrocytomas. A marker for anaplastic potential. Arch Pathol Lab Med 2001; 125: 613-24.
127. Katsetos CD, Del Valle L, Geddes JF, et al. Localization of the neuronal class III-tubulin in oligodendrogliomas: comparison with Ki-67 proliferative index and 1p/19q status. J Neuropathol Exp Neurol 2002; 61: 307-20.
128. Akasaka K, Maesawa C, Shibazaki M, et al. Loss of class III betatubulin induced by histone deacetylation is associated with chemosensitivity to paclitaxel in malignant melanoma cells. J Invest Dermatol. 2009; 129: 1516-26.
129. McCarroll JA, Gan PP, Liu M, Kavallaris M. III-Tubulin is a multifunctional protein involved in drug sensitivity and tumorigenesis in non-small cell lung cancer. Cancer Res. 2010; 70: 4995-5003.
130. Sève P, Reiman T, Lai R, et al. Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site. Cancer Chemother Pharmacol 2007; 60: 27-34.
131. Sève P, Reiman T, Isaac S, et al. Protein abundance of class III beta-tubulin but not Delta2-alpha-tubulin or tau is related to paclitaxel response in carcinomas of unknown primary site. Anticancer Res. 2008; 28: 1161-7.
132. Okuda K, Sasaki H, Dumontet C, et al. Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected nonsmall cell lung cancer. Lung Cancer 2008; 62: 105-12.
133. Dumontet C, Krajewska M, Treilleux I, et al. BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy. Clin Cancer Res 2010; 16: 3988-97.
134. Raspaglio G, De Maria I, Filippetti F, et al. HuR regulates betatubulin isotype expression in ovarian cancer. Cancer Res. 2010; 70: 5891-900.
135. Ferrandina G, Martinelli E, Zannoni GF, et al. Expression of class III beta tubulin in cervical cancer patients administered preoperative radiochemotherapy: correlation with response to treatment and clinical outcome. Gynecol Oncol 2007; 104: 326-30.
136. Aoki D, Oda Y, Hattori S, et al. Overexpression of class III betatubulin predicts good response to taxane-based chemotherapy in ovarian clear cell adenocarcinoma. Clin Cancer Res 2009; 15: 1473-80.
137. Mao Y, Zhou L, Zhu W, et al. Proliferative status of tumor stem cells may be correlated with malignancy grade of human astrocytomas. Front Biosci 2007; 12: 2252-9.
138. Katsetos CD, Dráberová E, mejkalová B, et al. Class III-tubulin and-tubulin are co-expressed and form complexes in human glioblastoma cells. Neurochem Res 2007; 32: 1387-98.
139. Martinez-Diaz H, Kleinschmidt-DeMasters BK, Powell SZ, Yachnis AT. Giant cell glioblastoma and pleomorphic xanthoastrocytoma show different immunohistochemical profiles for neuronal antigens and p53 but share reactivity for class III-tubulin. Arch Pathol Lab Med 2003; 127: 1187-91.
140. Laggner U, Pipp I, Budka H, Hainfellner JA, Preusser M. Immunohistochemical detection of class III beta-tubulin in primary brain tumours: variable expression in most tumour types limits utility as a differential diagnostic marker. Histopathology. 2007; 50: 949-52.
141. Ikota H, Kinjo S, Yokoo H, Nakazato Y. Systematic immunohistochemical profiling of 378 brain tumors with 37 antibodies using tissue microarray technology. Acta Neuropathol (Berl) 2006; 111: 475-82.
142. Rieske P, Azizi SA, Augelli B, Gaughan J, Krynska B. A population of human brain parenchymal cells express markers of glial, neuronal and early neural cells and differentiate into cells of neuronal and glial lineages. Eur J Neurosci 2007; 25: 31-3.
143. Walss-Bass C, Xu K, David S, Fellous A, Ludueña RF. Occurrence of nuclear beta(II)-tubulin in cultured cells. Cell Tissue Res. 2002; 308: 215-23.
144. Yeh IT, Ludueña RF. The betaII isotype of tubulin is present in the cell nuclei of a variety of cancers. Cell Motil Cytoskeleton 2004; 57: 96-106.
145. Kourmouli N, Dialynas G, Petraki C, et al. Binding of heterochromatin protein 1 to the nuclear envelope is regulated by a soluble form of tubulin. J Biol Chem. 2001; 276: 13007-14.
146. Verdier-Pinard P, Shahabi S, Wang F, et al. Detection of human V-tubulin expression in epithelial cancer cell lines by tubulin proteomics. Biochemistry 2005; 44: 15858-70.
147. Hiser L, Aggarwal A, Young R, et al. Comparison of beta-tubulin mRNA and protein levels in 12 human cancer cell lines. Cell Motil Cytoskeleton 2006; 63: 41-52.
148. Bhattacharya R, Frankfurter A, Cabral F. A minor-tubulin essential for mammalian cell proliferation. Cell Motil Cytoskeleton 2008; 65: 708-20.
149. Cucchiarelli V, Hiser L, Smith H, et al. Beta-tubulin isotype classes II and V expression patterns in nonsmall cell lung carcinomas. Cell Motil Cytoskeleton 2008; 65: 675-85.
150. INK4A promoter methylation occur together in preinvasive lesions and carcinomas of the breast. Ann Oncol 2009; 20: 441-8.
151. Niu Y, Liu T, Tse GM, et al. Increased expression of centrosomal-tubulin in atypical ductal hyperplasia and carcinoma of the breast. Cancer Sci 2009; 100: 580-7.
152. Katsetos CD, Reddy G, Dráberová E, et al. Altered cellular distribution and subcellular sorting of-tubulin in astrocytic gliomas and human glioblastoma cell lines. J Neuropathol Exp Neurol 2006; 65: 465-77.
153. Loh JK, Lieu AS, Chou CH, et al. Differential expression of centrosomal proteins at different stages of human glioma. BMC Cancer 2010; 10: 268.
154. Rickman DS, Bobek MP, Misek DE, et al. Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res 2001; 61: 6885-91.
155. Caracciolo V, D'Agostino L, Dráberová E, et al. Differential expression and cellular distribution of-tubulin and III-tubulin in medulloblastomas and human medulloblastoma cell lines. J Cell Physiol 2010; 223: 519-29.
156. Syed MI, Syed S, Minty F, et al. Gamma tubulin: a promising indicator of recurrence in squamous cell carcinoma of the larynx. Otolaryngol Head Neck Surg 2009; 140: 498-504.
157. Maounis N, Mahera E, Dráberová E, et al. Overexpression of gamma tubulin in nonsmall cell lung cancer. Histopathology 2010; 57 (Suppl. 1): 227 (Abstr).
158. Mialhe A, Lafanechère L, Treilleux I, et al. Tubulin detyrosination is a frequent occurrence in breast cancers of poor prognosis. Cancer Res. 2001; 61: 5024-7.
159. Miller LM, Menthena A, Chatterjee C, et al. Increased levels of a unique post-translationally modified betaIVb-tubulin isotype in liver cancer. Biochemistry 2008; 47: 7572-82.
160. Perdiz D, Mackeh R, Poüs C, Baillet A. The ins and outs of tubulin acetylation: more than just a post-translational modification? Cell Signal 2011; 23: 763-71.
161. Bertos NR, Gilquin B, Chan GK, Yen TJ, Khochbin S, Yang XJ. Role of the tetradecapeptide repeat domain of human histone deacetylase 6 in cytoplasmic retention. J Biol Chem 2004; 279: 48246-54.
162. Hubbert C, Guardiola A, Shao R, et al. HDAC6 is a microtubuleassociated deacetylase. Nature 2002; 417: 455-8.
163. Zhang Y, Li N, Caron C, Matthias G, Hess D, Khochbin S, Matthias P. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J 2003; 22: 1168-79.
164. Tran AD, Marmo TP, Salam AA, et al. HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesions. J Cell Sci 2007; 120: 1469-79.
165. Suzuki J, Chen YY, Scott GK, et al. Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression. Clin Cancer Res 2009; 15: 3163-71.
166. Ninios YP, Sekeri-Pataryas KE, Sourlingas TG. Differential sensitivity of human leukemic cell lines to the histone deacetylase inhibitor, trichostatin A. Leuk Res 2010; 34: 786-92.
167. Dráberová E, Vinopal S, Morfini G, et al. Microtubule-severing ATPase spastin in glioblastoma: increased expression in human glioblastoma cell lines and inverse roles in cell motility and proliferation. J Neuropathol Exp Neurol 2011; 70: 811-26.
168. Vale RD. Severing of stable microtubules by a mitotically activated protein in Xenopus egg extracts. Cell 1991; 64: 827-39.
169. McNally FJ, Thomas S. Katanin is responsible for the M-phase microtubule-severing activity in Xenopus eggs. Mol Biol Cell 1998; 9: 1847-61.
170. Perez EA. Microtubule inhibitors: differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther 2009; 8: 2086-95.
171. Morris PG, Fornier, MN. Microtubule active agents: beyond the taxane frontier. Clin Cancer Res 2008; 14: 7167-72.
172. Nettles JH, Li H, Cornett B, Krahn JM, Snyder JP, Downing KH. The binding mode of epothilone A on,-tubulin by electron crystallography. Science 2004; 305: 866-9.
173. Rieder CL, Maiato H. Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev Cell 2004; 7: 637-51.
174. Gascoigne KE, Taylor SS. How do anti-mitotic drugs kill cancer cells? J Cell Sci 2009; 122: 2579-85.
175. Brito DA, Rieder CL. The ability to survive mitosis in the presence of microtubule poisons differs significantly between human nontransformed (RPE 1) and cancer (U2OS, HeLa) cells. Cell Motil Cytoskeleton 2009; 66: 437-47.
176. Gascoigne KE, Taylor SS. Cancer cells display profound intra and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 2008; 14: 111-22.
177. Brito DA, Rieder CL. Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint. Curr Biol 2006; 16: 1194-1200.
178. Shi J, Orth JD, Mitchison T. Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5. Cancer Res. 2008; 68: 3269-76.
179. Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 1993; 90: 9552-6.
180. Berrieman HK, Lind MJ, Cawkwell L. Do-tubulin mutations have a role in resistance to chemotherapy? Lancet Oncol 2004; 5: 158-64.
181. Lu Q, Ludueña RF. Removal of III isotype enhances taxol induced microtubule assembly. Cell Struct Funct 1993; 18: 173-82.
182. Kavallaris M, Kuo DY, Burkhart CA, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 1997; 100: 1282-93.
183. Kavallaris M, Burkhart CA, Horwitz SB. Antisense oligonucleotides to class III-tubulin sensitize drug-resistant cells to Taxol. Br J Cancer 1999; 80: 1020-5.
184. Kamath K, Wilson L, Cabral F, Jordan, MA. III-Tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem 2005; 280: 12902-7.
185. Gan PP, Pasquier E, Kavallaris M. Class III-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res 2007; 67: 9356-63.
186. Cicchillitti L, Penci R, Di Michele M, et al. Proteomic characterization of cytoskeletal and mitochondrial class III-tubulin. Mol Cancer Ther 2008; 7: 2070-9.
187. Freedman H, Huzil JT, Luchko T, Ludueña RF, Tuszynski JA. Identification and characterization of an intermediate taxol binding site within microtubule nanopores and a mechanism for tubulin isotype binding selectivity. J Chem Inf Model 2009; 49: 424-36.
188. De Donato M, Mariani M, Petrella L, et al. Class III-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer. J Cell Physiol 2012; 227: 1034-41.
189. Mariani M, Shahabi S, Sieber S, Scambia G, Ferlini C. Class III-tubulin (TUBB3): more than a biomarker in solid tumors? Curr Mol Med 2011; 11: 726-31.
190. Raspaglio G, Filippetti F, Prislei S, et al. Hypoxia induces class III-tubulin gene expression by HIF-1alpha binding to its 3' flanking region. Gene 2008; 409: 100-8.
191. Ferlini C, Raspaglio G, Mozzetti S, et al. The seco-taxane IDN5390 is able to target class III-tubulin and to overcome paclitaxel resistance. Cancer Res 2005; 65: 2397-405.
192. Magnani M, Ortuso F, Soro S, Alcaro S, Tramontano A, Botta M. The I/ III-tubulin isoforms and their complexes with antimitotic agents. Docking and molecular dynamics studies. FEBS J 2006; 273: 3301-10.
193. Galmarini CM, Treilleux I, Cardoso F, et al. Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel. Clin Cancer Res 2008; 14: 4511-6.
194. Béghin A, Matera EL, Brunet-Manquat S, Dumontet C. Expression of Arl2 is associated with p53 localization and chemosensitivity in a breast cancer cell line. Cell Cycle 2008; 7: 3074-82.
195. Saussede-Aim J, Matera EL, Ferlini C, Dumontet C. Beta3-tubulin is induced by estradiol in human breast carcinoma cells through an estrogen-receptor dependent pathway. Cell Motil Cytoskeleton 2009; 66: 378-88.
196. Saussede-Aim, J, Matera EL, Herveau S, Rouault JP, Ferlini C, Dumontet C. Vinorelbine induces beta3-tubulin gene expression through an AP-1 site. Anticancer Res 2009; 29: 3003-9.
197. Beghin A, Galmarini CM, Dumontet C. Tubulin folding pathways: implication in the regulation of microtubule dynamics. Curr Cancer Drug Targets. 2007; 7: 697-703.
198. Hage-Sleiman R, Herveau S, Matera EL, Laurier JF, Dumontet C. Silencing of tubulin binding cofactor C modifies microtubule dynamics and cell cycle distribution and enhances sensitivity to gemcitabine in breast cancer cells. Mol Cancer Ther. 2011; 10: 303-12.
199. Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone (BMS 247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007; 25: 3399-406.
200. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007; 25: 5210-7.
201. Ten Bokkel Huinink WW, Sufliarsky J, Smit WM, et al. Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a Phase I, open-label, doseescalation study. J Clin Oncol 2009; 27: 3097-103.
202. Vansteenkiste J, Lara PN Jr, Le Chevalier T, et al. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed firstline platinumbased chemotherapy. J Clin Oncol 2007; 25: 3448-55.
203. Mozzetti S, Iantomasi R, De Maria I, et al. Molecular mechanisms of patupilone resistance. Cancer Res 2008; 68: 10197-204.
204. Sabbatini P, Spriggs DR. Epothilones: better or more of the same? J Clin Oncol 2009: 27: 3079-81.
205. Lee FY, Borzilleri R, Fairchild CR, et al. Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Cancer Chemother Pharmacol 2008; 63: 157-66.
206. O'Reilly T, Wartmann M, Brueggen J, et al. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo. Cancer Chemother Pharmacol 2008; 62: 1045-54.
207. Galmarini CM. Sagopilone, a microtubule stabilizer for the potential treatment of cancer. Curr Opin Invest Drugs 2009; 10: 1359-71.
208. Hoffmann J, Fichtner I, Lemm M, et al. Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases. Neuro Oncol 2009; 11: 158-66.
209. Silvani A, Gaviani P, Fiumani A, et al. Systemic sagopilone (ZK-EPO) treatment of patients with recurrent malignant gliomas. J Neurooncol 2009; 95: 61-4.
210. Gan PP, McCarroll JA, Po'uha ST, Kamath K, Jordan MA, Kavallaris M. Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of III-tubulin. Mol Cancer Ther 2010; 9: 1339-48.
211. Gan PP, McCarroll JA, Byrne FL, Garner J, Kavallaris M. Specific-tubulin isotypes can functionally enhance or diminish epothilone B sensitivity in non-small cell lung cancer cells. PLoS One 2011; 6: e21717.
212. Tseng CY, Mane JY, Winter P, et al. Quantitative analysis of the effect of tubulin isotype expression on sensitivity of cancer cell lines to a set of novel colchicine derivatives. Mol Cancer 2010; 9: 131.